Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.69 |
| ▸ | CLK2 | P49760 | 11/20 | 0.69 |
| ▸ | CLK3 | P49761 | 10/20 | 0.69 |
| ▸ | WNT1 | P04628 | 11/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804020 | 0.95 | DYRK1A (0.75) | GSK3BKCNH2DYRK1ACLK2CLK3 | |
| SCHEMBL14804128 | 0.92 | DYRK1A (0.80) | GSK3BKCNH2DYRK1ACLK2CLK3 | |
| SCHEMBL14804024 | 0.92 | DYRK1A (0.80) | GSK3BKCNH2DYRK1ACLK2CLK3 | |
| SCHEMBL14792122 | 0.92 | DYRK1A (0.72) | GSK3BKCNH2DYRK1ACLK2CLK3 | |
| SCHEMBL14792182 | 0.92 | DYRK1A (0.72) | GSK3BKCNH2DYRK1ACLK2CLK3 | |
| SCHEMBL14804423 | 0.92 | DYRK1A (0.77) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14804417 | 0.92 | CLK2 (0.80) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14792197 | 0.92 | DYRK1A (0.75) | GSK3BKCNH2DYRK1ACLK2CLK3 | |
| SCHEMBL14804127 | 0.92 | DYRK1A (0.79) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14804019 | 0.92 | DYRK1A (0.79) | DYRK1ACLK2CLK3WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20180185343-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-05 | — | — | US | disclosed |
| US-9221793-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | SAMUMED, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140045815-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS | SAMUMED, LLC (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130079329-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045815-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, WNT1, WNT3A | GSK3B 5/4885KCNH2 3908/4885DYRK1A 733/4885 |
| US-20180185343-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, CTNNB1, WNT3A | GSK3B 5/4885KCNH2 3747/4885DYRK1A 227/4885 |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT3, WNT3A, WNT1 | GSK3B 5/4885KCNH2 3993/4885DYRK1A 167/4885 |
| US-20130079329-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, WNT1, WNT3A | GSK3B 5/4885KCNH2 3908/4885DYRK1A 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.